Physician profile
Leonard E Bienkowski
NPI 1205819984
$6,480.32
in general payments reported to CMS, 2019-2025
32 companies · $400 in 2025
The $400 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $752 · 2021: $1,232 · 2022: $346 · 2023: $549 · 2024: $1,152 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.24 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $1,850.51 | 2019-2021 | |
| Renovia INC | $1,187.56 | 2019-2021 | |
| Abbvie INC. | $517.92 | 2019-2025 | Orilissa |
| Mayne Pharma Commercial LLC | $496.86 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $335.46 | 2019-2025 | |
| Daiichi Sankyo INC. | $289.76 | 2022-2024 | Injectafer |
| Amgen INC. | $253.15 | 2020-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $200.46 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $184.12 | 2023-2025 | Gemtesa, Myfembree |
| Aspira Women'S Health INC | $125.20 | 2021-2024 | Ova1 |
| Amag Pharmaceuticals, INC. | $111.81 | 2019-2020 | |
| Millicent US INC | $97.18 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $90.88 | 2021-2024 | Summit Doppler, Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $77.24 | 2020-2025 | Gardasil 9 |
| Shield Therapeutics INC | $74.54 | 2023-2024 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $70.12 | 2023-2024 | Axonics |
| Allergan, INC. | $68.80 | 2019-2020 | |
| Therapeuticsmd, INC. | $63.18 | 2019-2021 | |
| Organon LLC | $62.14 | 2023-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $58.79 | 2021-2024 | Aptima |
| Exeltis, USA INC. | $57.38 | 2020-2024 | Slynd |
| Avion Pharmaceuticals | $41.81 | 2019-2021 | |
| Myovant Sciences INC. | $36.00 | 2021-2022 | |
| Evofem Biosciences, INC. | $23.24 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $18.06 | 2023 | Kristalose |
| Medtronic, INC. | $16.59 | 2022 | |
| Distalmotion US | $15.07 | 2025 | Dexter L6 Robot |
| Ethicon US, LLC | $14.50 | 2023 | Vistaseal, Dermabond, Stratafix |
| Sage Therapeutics, LLC | $14.09 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $13.97 | 2021 | |
| Tactile Systems Technology INC | $13.93 | 2023 | Flexitouch Plus, Entre Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Bienkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.